Prospects of immunotherapy for cancer

[1]	June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science 2018; 359(6382): 1361–1365 CrossRef Pubmed Google scholar

[2]	Bournazos S, Wang TT, Dahan R, Maamary J, Ravetch JV. Signaling by antibodies: recent progress. Annu Rev Immunol 2017; 35(1): 285–311 CrossRef Pubmed Google scholar

[3]	Newick K, O’Brien S, Moon E, Albelda SM. CAR T cell therapy for solid tumors. Annu Rev Med 2017; 68(1): 139–152 CrossRef Pubmed Google scholar

[4]	Lerner RA. Combinatorial antibody libraries: new advances, new immunological insights. Nat Rev Immunol 2016; 16(8): 498–508 CrossRef Pubmed Google scholar

[5]	Park JH, Geyer MB, Brentjens RJ. CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date. Blood 2016; 127(26): 3312–3320 CrossRef Pubmed Google scholar

[6]	Jackson HJ, Rafiq S, Brentjens RJ. Driving CAR T-cells forward. Nat Rev Clin Oncol 2016; 13(6): 370–383 CrossRef Pubmed Google scholar

[7]	Ramos CA, Heslop HE, Brenner MK. CAR-T cell therapy for lymphoma. Annu Rev Med 2016; 67(1): 165–183 CrossRef Pubmed Google scholar

Compliance with ethics guidelines

Zhinan Chen declares no conflict of interests. This manuscript does not involve a research protocol requiring approval by the relevant institutional review board or ethics committee.